Skip to main content

Anticholinergic Agents in Respiratory Diseases

  • Chapter
Allergic Diseases

Part of the book series: Current Clinical Practice ((CCP))

  • 1302 Accesses

Abstract

Anticholinergic agents play an adjunctive role in the treatment of allergic respiratory diseases. Their formal indication in lung disease is for emphysema. However, they are useful in some asthmatics. In upper airway disease they are very effective agents to treat anterior rhinorrhea of the common cold or due to allergic or nonallergic rhinitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  • Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–224.

    Article  PubMed  CAS  Google Scholar 

  • Ducharme F, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatr 1998;133:479–485.

    Article  PubMed  CAS  Google Scholar 

  • Garrett JE, Town GI, Rodwell P, Kelly A. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. J Allergy Clin Immunol 1997;100:165–170.

    Article  PubMed  CAS  Google Scholar 

  • Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995;107:401–405.

    PubMed  CAS  Google Scholar 

  • McDonald NJ, Bara AI, McKean M. Anticholinergic therapy for chronic asthma in children over two years of age. The Cochrane Database of Systematic Reviews 2003; issue 1. Meltzer EO, Spector SL, eds. Anticholinergic therapy for allergic and nonallergic rhinitis and the common cold. J Allergy Clin Immunol 1995;95 (no 5, pt 2):1065–1152.

    Google Scholar 

  • Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998;339:1030–1035.

    Article  PubMed  CAS  Google Scholar 

  • Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest 2002;121:1977–1987.

    Article  PubMed  CAS  Google Scholar 

  • Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002;19:209–216.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Rodriguez, J.L. (2007). Anticholinergic Agents in Respiratory Diseases. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-382-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-382-0_22

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-603-0

  • Online ISBN: 978-1-59745-382-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics